EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents

Ming-Jie Han, Miaomiao Pan, Genhui Xiao, Ying Yuan, Shawn Chen iD, Zhiyang Zou iD

Molecules · 2023

DOI: 10.3390/molecules28124628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Ming-Jie Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of DMPK & Tox, Global Health Drug Discovery Institute, Zhongguancun Dongsheng International Science Park, Beijing 100192, China. Hauptthemen laut MEDLINE: Diterpenes, Polycyclic Compounds, Onchocerciasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, Bill & Melinda Gates Foundation, GHDDI sponsors in Beijing, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pleuromutilins are a group of antibiotics derived from the naturally occurring compound. The recent approval of lefamulin for both intravenous and oral doses in humans to treat community-acquired bacterial pneumonia has prompted investigations in modifying the structure to broaden the antibacterial spectrum, enhance the activity, and improve the pharmacokinetic properties. AN11251 is a C(14)-functionalized pleuromutilin with a boron-containing heterocycle substructure. It was demonstrated to be an anti-Wolbachia agent with therapeutic potential for Onchocerciasis and lymphatic filariasis. Here, the in vitro and in vivo PK parameters of AN11251 were measured including PPB, intrinsic clearance, half-life, systemic clearance, and volume of distribution. The results indicate that the benzoxaborole-modified pleuromutilin possesses good ADME and PK properties. AN11251 has potent activities against the Gram-positive bacterial pathogens tested, including various drug-resistant strains, and against the slow-growing mycobacterial species. Finally, we employed PK/PD modeling to predict the human dose for treatment of disease caused by Wolbachia, Gram-positive bacteria, or Mycobacterium tuberculosis, which might facilitate the further development of AN11251.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiterpenesPolycyclic CompoundsOnchocerciasisHumansAnti-Bacterial AgentsBoronBacteriaGram-Positive BacteriaMicrobial Sensitivity TestsPleuromutilins

Stichwörter der Autor:innen

AN11251anti-Wolbachiaantibacterialdose predictionin vitro ADMEpharmacokineticspleuromutilins

Substanzen

Anti-Bacterial AgentsBoronDiterpenesPolycyclic CompoundsPleuromutilins

Autor:innen und Institutionen

  • Department of DMPK & Tox, Global Health Drug Discovery Institute, Zhongguancun Dongsheng International Science Park, Beijing 100192, China.
  • Department of TB Biology, Global Health Drug Discovery Institute, Zhongguancun Dongsheng International Science Park, Beijing 100192, China.

ORCID-Profile: Shawn Chen, Zhiyang Zou

Förderung

  • Bill & Melinda Gates Foundation
  • Bill & Melinda Gates Foundation
  • GHDDI sponsors in Beijing, China

Zitieren

APA

Han, M. J., Pan, M., Xiao, G., Yuan, Y., Chen, S., & Zou, Z. (2023). Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents. Molecules. https://doi.org/10.3390/molecules28124628

Vancouver

Han MJ, Pan M, Xiao G, Yuan Y, Chen S, Zou Z. Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents. Molecules. 2023. doi:10.3390/molecules28124628

BibTeX
@article{Han2023,
  author = {Han, Ming-Jie and Pan, Miaomiao and Xiao, Genhui and Yuan, Ying and Chen, Shawn and Zou, Zhiyang},
  title = {Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28124628}
}
Kostenlos starten →